Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852966 | 1.00 | MAPT (0.41) | MAPTNPSR1TBXAS1KMT2AMEN1 | |
| SCHEMBL23229139 | 0.84 | GAA (0.58) | MAPTNPSR1TBXAS1KMT2AMEN1 | |
| SCHEMBL23218748 | 0.82 | MAPT (0.46) | MAPTNPSR1TBXAS1KMT2AMEN1 | |
| SCHEMBL29852811 | 0.82 | MAPT (0.46) | MAPTNPSR1TBXAS1KMT2AMEN1 | |
| SCHEMBL23218949 | 0.82 | TBXAS1 (0.41) | MAPTNPSR1TBXAS1KMT2AMEN1 | |
| SCHEMBL29853036 | 0.82 | MEN1 (0.47) | MAPTNPSR1TBXAS1KMT2AMEN1 | |
| SCHEMBL23218096 | 0.82 | MEN1 (0.47) | MAPTNPSR1TBXAS1KMT2AMEN1 | |
| SCHEMBL23218568 | 0.81 | TBXAS1 (0.42) | MAPTNPSR1TBXAS1PTGDR2NPC1 | |
| SCHEMBL23229138 | 0.81 | POLB (0.49) | MAPTNPSR1TBXAS1KMT2AMEN1 | |
| SCHEMBL23218880 | 0.80 | TBXAS1 (0.40) | MAPTNPSR1TBXAS1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | MAPT 4793/4885NPSR1 2875/4885TBXAS1 963/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | MAPT 3561/4885NPSR1 3198/4885TBXAS1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.